Inhibition of Nr4a receptors enhances antitumor immunity by breaking treg-mediated immune tolerance

Sana Hibino, Shunsuke Chikuma, Taisuke Kondo, Minako Ito, Hiroko Nakatsukasa, Setsuko Omata-Mise, Akihiko Yoshimura

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Enhanced infiltration of regulatory T cells (Treg) into tumor tissue is detrimental to patients with cancer and is closely associated with poor prognosis as they create an immunosuppressive state that suppresses antitumor immune responses. Therefore, breaking Treg-mediated immune tolerance is important when considering cancer immunotherapy. Here, we show that the Nr4a nuclear receptors, key transcription factors maintaining Treg genetic programs, contribute to Treg-mediated suppression of antitumor immunity in the tumor microenvironment. Mice lacking Nr4a1 and Nr4a2 genes specifically in Tregs showed resistance to tumor growth in transplantation models without exhibiting any severe systemic autoimmunity. The chemotherapeutic agent camptothecin and a common cyclooxygenase-2 inhibitor were found to inhibit transcriptional activity and induction of Nr4a factors, and they synergistically exerted antitumor effects. Genetic inactivation or pharmacologic inhibition of Nr4a factors unleashed effector activities of CD8þ cytotoxic T cells and evoked potent antitumor immune responses. These findings demonstrate that inactivation of Nr4a in Tregs breaks immune tolerance toward cancer, and pharmacologic modulation of Nr4a activity may be a novel cancer treatment strategy targeting the immunosuppressive tumor microenvironment. Significance: This study reveals the role of Nr4a transcription factors in Treg-mediated tolerance to antitumor immunity, with possible therapeutic implications for developing effective anticancer therapies

Original languageEnglish
Pages (from-to)3027-3040
Number of pages14
JournalCancer Research
Volume78
Issue number11
DOIs
Publication statusPublished - 2018 Jun 1

Fingerprint

Immune Tolerance
Immunity
Neoplasms
Tumor Microenvironment
Immunosuppressive Agents
Transcription Factors
Camptothecin
Cyclooxygenase 2 Inhibitors
Regulatory T-Lymphocytes
Cytoplasmic and Nuclear Receptors
Autoimmunity
Immunotherapy
Therapeutics
Transplantation
T-Lymphocytes
Growth
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Inhibition of Nr4a receptors enhances antitumor immunity by breaking treg-mediated immune tolerance. / Hibino, Sana; Chikuma, Shunsuke; Kondo, Taisuke; Ito, Minako; Nakatsukasa, Hiroko; Omata-Mise, Setsuko; Yoshimura, Akihiko.

In: Cancer Research, Vol. 78, No. 11, 01.06.2018, p. 3027-3040.

Research output: Contribution to journalArticle

@article{becabac91ced4f3891c2d953ece7fb2a,
title = "Inhibition of Nr4a receptors enhances antitumor immunity by breaking treg-mediated immune tolerance",
abstract = "Enhanced infiltration of regulatory T cells (Treg) into tumor tissue is detrimental to patients with cancer and is closely associated with poor prognosis as they create an immunosuppressive state that suppresses antitumor immune responses. Therefore, breaking Treg-mediated immune tolerance is important when considering cancer immunotherapy. Here, we show that the Nr4a nuclear receptors, key transcription factors maintaining Treg genetic programs, contribute to Treg-mediated suppression of antitumor immunity in the tumor microenvironment. Mice lacking Nr4a1 and Nr4a2 genes specifically in Tregs showed resistance to tumor growth in transplantation models without exhibiting any severe systemic autoimmunity. The chemotherapeutic agent camptothecin and a common cyclooxygenase-2 inhibitor were found to inhibit transcriptional activity and induction of Nr4a factors, and they synergistically exerted antitumor effects. Genetic inactivation or pharmacologic inhibition of Nr4a factors unleashed effector activities of CD8{\th} cytotoxic T cells and evoked potent antitumor immune responses. These findings demonstrate that inactivation of Nr4a in Tregs breaks immune tolerance toward cancer, and pharmacologic modulation of Nr4a activity may be a novel cancer treatment strategy targeting the immunosuppressive tumor microenvironment. Significance: This study reveals the role of Nr4a transcription factors in Treg-mediated tolerance to antitumor immunity, with possible therapeutic implications for developing effective anticancer therapies",
author = "Sana Hibino and Shunsuke Chikuma and Taisuke Kondo and Minako Ito and Hiroko Nakatsukasa and Setsuko Omata-Mise and Akihiko Yoshimura",
year = "2018",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-17-3102",
language = "English",
volume = "78",
pages = "3027--3040",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Inhibition of Nr4a receptors enhances antitumor immunity by breaking treg-mediated immune tolerance

AU - Hibino, Sana

AU - Chikuma, Shunsuke

AU - Kondo, Taisuke

AU - Ito, Minako

AU - Nakatsukasa, Hiroko

AU - Omata-Mise, Setsuko

AU - Yoshimura, Akihiko

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Enhanced infiltration of regulatory T cells (Treg) into tumor tissue is detrimental to patients with cancer and is closely associated with poor prognosis as they create an immunosuppressive state that suppresses antitumor immune responses. Therefore, breaking Treg-mediated immune tolerance is important when considering cancer immunotherapy. Here, we show that the Nr4a nuclear receptors, key transcription factors maintaining Treg genetic programs, contribute to Treg-mediated suppression of antitumor immunity in the tumor microenvironment. Mice lacking Nr4a1 and Nr4a2 genes specifically in Tregs showed resistance to tumor growth in transplantation models without exhibiting any severe systemic autoimmunity. The chemotherapeutic agent camptothecin and a common cyclooxygenase-2 inhibitor were found to inhibit transcriptional activity and induction of Nr4a factors, and they synergistically exerted antitumor effects. Genetic inactivation or pharmacologic inhibition of Nr4a factors unleashed effector activities of CD8þ cytotoxic T cells and evoked potent antitumor immune responses. These findings demonstrate that inactivation of Nr4a in Tregs breaks immune tolerance toward cancer, and pharmacologic modulation of Nr4a activity may be a novel cancer treatment strategy targeting the immunosuppressive tumor microenvironment. Significance: This study reveals the role of Nr4a transcription factors in Treg-mediated tolerance to antitumor immunity, with possible therapeutic implications for developing effective anticancer therapies

AB - Enhanced infiltration of regulatory T cells (Treg) into tumor tissue is detrimental to patients with cancer and is closely associated with poor prognosis as they create an immunosuppressive state that suppresses antitumor immune responses. Therefore, breaking Treg-mediated immune tolerance is important when considering cancer immunotherapy. Here, we show that the Nr4a nuclear receptors, key transcription factors maintaining Treg genetic programs, contribute to Treg-mediated suppression of antitumor immunity in the tumor microenvironment. Mice lacking Nr4a1 and Nr4a2 genes specifically in Tregs showed resistance to tumor growth in transplantation models without exhibiting any severe systemic autoimmunity. The chemotherapeutic agent camptothecin and a common cyclooxygenase-2 inhibitor were found to inhibit transcriptional activity and induction of Nr4a factors, and they synergistically exerted antitumor effects. Genetic inactivation or pharmacologic inhibition of Nr4a factors unleashed effector activities of CD8þ cytotoxic T cells and evoked potent antitumor immune responses. These findings demonstrate that inactivation of Nr4a in Tregs breaks immune tolerance toward cancer, and pharmacologic modulation of Nr4a activity may be a novel cancer treatment strategy targeting the immunosuppressive tumor microenvironment. Significance: This study reveals the role of Nr4a transcription factors in Treg-mediated tolerance to antitumor immunity, with possible therapeutic implications for developing effective anticancer therapies

UR - http://www.scopus.com/inward/record.url?scp=85048057054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048057054&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-3102

DO - 10.1158/0008-5472.CAN-17-3102

M3 - Article

C2 - 29559474

AN - SCOPUS:85048057054

VL - 78

SP - 3027

EP - 3040

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 11

ER -